These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33749172)

  • 1. Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.
    Kalf RRJ; Vreman RA; Delnoij DMJ; Bouvy ML; Goettsch WG
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00742. PubMed ID: 33749172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging health technology assessment and healthcare quality improvement using international consortium of health outcomes measurement standard sets.
    Kalf RRJ; Zuidgeest M; Delnoij DMJ; Bouvy ML; Goettsch WG
    Int J Technol Assess Health Care; 2021 Dec; 38(1):e6. PubMed ID: 36317685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing adaptability and standardisation: insights from 27 routinely implemented ICHOM standard sets.
    Benning L; Das-Gupta Z; Sousa Fialho L; Wissig S; Tapela N; Gaunt S
    BMC Health Serv Res; 2022 Nov; 22(1):1424. PubMed ID: 36443786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
    Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
    Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
    Efthymiadou O; Kanavos P
    Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common patient-reported outcomes across ICHOM Standard Sets: the potential contribution of PROMIS®.
    Terwee CB; Zuidgeest M; Vonkeman HE; Cella D; Haverman L; Roorda LD
    BMC Med Inform Decis Mak; 2021 Sep; 21(1):259. PubMed ID: 34488730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.
    Yang WW; Juan YC; Wu GH; Pwu RF
    Drug Saf; 2024 Apr; 47(4):289-299. PubMed ID: 38113017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
    Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
    Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
    Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
    Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
    Monnickendam G; Zhu M; McKendrick J; Su Y
    Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.
    Sarri G; Hernandez LG
    J Comp Eff Res; 2024 Sep; 13(9):e240061. PubMed ID: 39132748
    [No Abstract]   [Full Text] [Related]  

  • 18. Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.
    Vreman RA; Naci H; Goettsch WG; Mantel-Teeuwisse AK; Schneeweiss SG; Leufkens HGM; Kesselheim AS
    Clin Pharmacol Ther; 2020 Aug; 108(2):350-357. PubMed ID: 32236959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
    Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
    Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.